This company listing is no longer active
Intercept Pharmaceuticals (ICPT *) Stock Overview
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ICPT * Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Intercept Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$329.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.27 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -83.98% |
| 5 Year Change | n/a |
| Change since IPO | -78.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| ICPT * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 0% | 0% | 0% |
Return vs Industry: ICPT * exceeded the MX Biotechs industry which returned -6% over the past year.
Return vs Market: ICPT * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| ICPT * volatility | |
|---|---|
| ICPT * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ICPT * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ICPT *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 341 | Jerry Durso | www.interceptpharma.com |
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development.
Intercept Pharmaceuticals, Inc. Fundamentals Summary
| ICPT * fundamental statistics | |
|---|---|
| Market cap | Mex$8.54b |
| Earnings (TTM) | -Mex$3.00b |
| Revenue (TTM) | Mex$5.09b |
Is ICPT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICPT * income statement (TTM) | |
|---|---|
| Revenue | US$294.52m |
| Cost of Revenue | US$983.00k |
| Gross Profit | US$293.54m |
| Other Expenses | US$466.84m |
| Earnings | -US$173.30m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.16 |
| Gross Margin | 99.67% |
| Net Profit Margin | -58.84% |
| Debt/Equity Ratio | 495.7% |
How did ICPT * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/12 20:21 |
| End of Day Share Price | 2023/03/15 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intercept Pharmaceuticals, Inc. is covered by 24 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Geoffrey Meacham | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |